PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $9,218,000 | -66.2% | 1,092,212 | -45.4% | 0.01% | -53.8% |
| Q1 2022 | $27,238,000 | -24.8% | 2,001,442 | +8.7% | 0.01% | -13.3% |
| Q4 2021 | $36,218,000 | -42.1% | 1,841,357 | -5.5% | 0.02% | -44.4% |
| Q3 2021 | $62,531,000 | -5.4% | 1,948,002 | -0.2% | 0.03% | -3.6% |
| Q2 2021 | $66,067,000 | -10.0% | 1,951,634 | -0.1% | 0.03% | -17.6% |
| Q1 2021 | $73,414,000 | +14.0% | 1,954,448 | +0.8% | 0.03% | +13.3% |
| Q4 2020 | $64,396,000 | +11.9% | 1,938,436 | +23.6% | 0.03% | 0.0% |
| Q3 2020 | $57,538,000 | +10.8% | 1,568,796 | -0.6% | 0.03% | +3.4% |
| Q2 2020 | $51,951,000 | +23.2% | 1,578,679 | -5.3% | 0.03% | 0.0% |
| Q1 2020 | $42,175,000 | -3.2% | 1,667,577 | +13.6% | 0.03% | +31.8% |
| Q4 2019 | $43,589,000 | – | 1,467,462 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $28,143,000 | 7.62% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $79,311,000 | 6.76% |
| Abingworth LLP | 1,435,106 | $19,503,000 | 5.53% |
| Penn Mutual Asset Management, LLC | 86,940 | $1,183,000 | 1.37% |
| MPM BioImpact LLC | 193,326 | $2,631,000 | 0.71% |
| Avidity Partners Management LP | 1,946,000 | $26,485,000 | 0.55% |
| StepStone Group LP | 422,085 | $5,745,000 | 0.43% |
| Rhenman & Partners Asset Management AB | 235,210 | $3,201,000 | 0.32% |
| Summit Rock Advisors, LP | 34,100 | $464,000 | 0.28% |
| Parkman Healthcare Partners LLC | 65,553 | $892,000 | 0.26% |